MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Limb Myorhythmia in a Patient With Anti-LGI-1 Encephalitis

    V. Mazo, P. Atit, S. Aradi, A. Rivera Cruz (Tampa, USA)

    Objective: N/a Background: Myorhythmia is a hyperkinetic involuntary movement disorder characterized by slow rhythmic movements (1-4 Hz), typically affecting cranial and/or limb muscles. Recognizing the…
  • 2025 International Congress

    Dance by Mammary: A Case of Paraneoplastic Chorea associated with Ductal Carcinoma in Situ

    A. Sajjad, K. Grajny (Allentown, USA)

    Objective: . Background: Paraneoplastic syndromes encompass a range of neurologic disorders triggered by an immune response to neoplasms, mediated by antibodies or cellular mechanisms. Paraneoplastic…
  • 2025 International Congress

    Diabetic Striatopathy Treated with Tetrabenazine: A Case Report and Discussion on a Commonly Forgotten Stroke Mimic

    A. Sovell, D. Klein (North Chicago, USA)

    Objective: Improve recognition of Diabetic Striatopathy (DS) as a stroke mimic causing acute hemichorea-hemiballismus, highlight factors leading to prolonged recovery, and propose tetrabenazine as a…
  • 2025 International Congress

    Constructing a multicenter neuroimaging dataset to unveil structural brain alterations in GNAO1-related disorders

    JD. Ortigoza-Escobar, J. Dominguez-Carral, J. Romagosa Pérez, A. Schteinschnaider, L. Soliani, D. Muñoz, M. Troncoso, MC. Miranda, JJ. Nieto, A. Camacho Salas, WG. Ludlam, K. Martemyanov, J. Muchart, CS. Stephan-Otto (Barcelona, Spain)

    Objective: This study aims to construct a reliable neuroimaging dataset to assess the impact of GNAO1 mutations on brain development. Background: GNAO1-related disorders (GNAO1-RD) are…
  • 2025 International Congress

    Remission of Tardive Dyskinesia in Patients Receiving Long-Term Valbenazine Treatment

    A. Cutler, L. Bahroo, K. Aldrich, E. Liu, C. Zeng, K. Farahmand (Syracuse, USA)

    Objective: To assess a potential threshold for remission of tardive dyskinesia (TD) during treatment with once-daily valbenazine, a uniquely selective vesicular monoamine transporter 2 inhibitor.…
  • 2025 International Congress

    Personalised Success: Evaluating Hemifacial Spasm Treatment with Goal Attainment Scale

    S. Maytharakcheep, O. Phokaewvarangkul, P. Panyakaew, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To assess the effectiveness of botulinum toxin A (BoNTA) therapy in treating  hemifacial spasm (HFS) patients using Goal Attainment Scale (GAS). Background: HFS is…
  • 2025 International Congress

    The Diabetic Dance: Hemichorea-Hemiballismus Syndrome On The Hyperglycemic Stage; A Case Report

    A. Kano (Zamboanga City, Philippines)

    Objective: 1. To present a case of hemichorea-hemiballismus syndrome secondary to non-ketotic hyperglycemia, highlighting its clinical presentation, diagnostic findings, and management approach. This report aims…
  • 2025 International Congress

    Long-term results of pallidal deep brain stimulation in patients with Huntington’s disease

    A. Gamaleya, A. Poddubskaya, S. Asriyants, A. Tomskiy (Moscow, Russian Federation)

    Objective: To analyze long-term results of pallidal (GPi) deep brain stimulation (DBS) in patients with Huntington's disease (HD). Background: In HD, DBS is suggested to…
  • 2025 International Congress

    Valbenazine Improves the Burden and Symptoms of Tardive Dyskinesia: Topline Results from the Phase 4 KINECT-PRO Study

    E. Dunayevich, A. Parameswaran, M. Bron, E. Franey, D. Sparta, C. Zeng, S. Mathias, J. Mcevoy (San Diego, USA)

    Objective: To evaluate the effects of once-daily valbenazine (VBZ) on the impacts of tardive dyskinesia (TD) using multiple patient-reported outcomes (PROs), including the psychometrically validated…
  • 2025 International Congress

    Huntington disease in a Patient with Extensive Psychiatric History

    A. Sim, A. Drozdov, D. Carrillo, L. Acosta (El Paso, USA)

    Objective: Huntington's Disease (HD) is an autosomal dominant neurodegenerative disorder resulting from an expansion of CAG trinucleotide repeats in the gene encoding the huntingtin protein.…
  • « Previous Page
  • 1
  • …
  • 229
  • 230
  • 231
  • 232
  • 233
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley